OBJECTIVE: Prognosis in women with ovarian cancer mainly depends on International Federation of Gynecology and Obstetrics stage and the ability to perform optimal cytoreductive surgery. Since ovarian cancer has a heterogeneous presentation and clinical course, predicting progression-free survival (PFS) and overall survival (OS) in the individual patient is difficult. The objective of this study was to determine predictors of PFS and OS in women with advanced stage epithelial ovarian cancer (EOC) after primary cytoreductive surgery and first-line platinum-based chemotherapy. DESIGN: Retrospective observational study. SETTING: Two teaching hospitals and one university hospital in the south-western part of the Netherlands. POPULATION: Women with advanced stage EOC. METHODS: All women who underwent primary cytoreductive surgery for advanced stage EOC followed by first-line platinum-based chemotherapy between January 1998 and October 2004 were identified. To investigate independent predictors of PFS and OS, a Cox' proportional hazard model was used. Nomograms were generated with the identified predictive parameters. MAIN OUTCOME MEASURES: The primary outcome measure was OS and the secondary outcome measures were response and PFS. RESULTS: A total of 118 women entered the study protocol. Median PFS and OS were 15 and 44 months, respectively. Preoperative platelet count (P = 0.007), and residual disease <1 cm (P = 0.004) predicted PFS with a optimism corrected c-statistic of 0.63. Predictive parameters for OS were preoperative haemoglobin serum concentration (P = 0.012), preoperative platelet counts (P = 0.031) and residual disease <1 cm (P = 0.028) with a optimism corrected c-statistic of 0.67. CONCLUSION: PFS could be predicted by postoperative residual disease and preoperative platelet counts, whereas residual disease, preoperative platelet counts and preoperative haemoglobin serum concentration were predictive for OS. The proposed nomograms need to be externally validated.
OBJECTIVE: Prognosis in women with ovarian cancer mainly depends on International Federation of Gynecology and Obstetrics stage and the ability to perform optimal cytoreductive surgery. Since ovarian cancer has a heterogeneous presentation and clinical course, predicting progression-free survival (PFS) and overall survival (OS) in the individual patient is difficult. The objective of this study was to determine predictors of PFS and OS in women with advanced stage epithelial ovarian cancer (EOC) after primary cytoreductive surgery and first-line platinum-based chemotherapy. DESIGN: Retrospective observational study. SETTING: Two teaching hospitals and one university hospital in the south-western part of the Netherlands. POPULATION: Women with advanced stage EOC. METHODS: All women who underwent primary cytoreductive surgery for advanced stage EOC followed by first-line platinum-based chemotherapy between January 1998 and October 2004 were identified. To investigate independent predictors of PFS and OS, a Cox' proportional hazard model was used. Nomograms were generated with the identified predictive parameters. MAIN OUTCOME MEASURES: The primary outcome measure was OS and the secondary outcome measures were response and PFS. RESULTS: A total of 118 women entered the study protocol. Median PFS and OS were 15 and 44 months, respectively. Preoperative platelet count (P = 0.007), and residual disease <1 cm (P = 0.004) predicted PFS with a optimism corrected c-statistic of 0.63. Predictive parameters for OS were preoperative haemoglobin serum concentration (P = 0.012), preoperative platelet counts (P = 0.031) and residual disease <1 cm (P = 0.028) with a optimism corrected c-statistic of 0.67. CONCLUSION: PFS could be predicted by postoperative residual disease and preoperative platelet counts, whereas residual disease, preoperative platelet counts and preoperative haemoglobin serum concentration were predictive for OS. The proposed nomograms need to be externally validated.
Authors: U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert Journal: Geburtshilfe Frauenheilkd Date: 2013-09 Impact factor: 2.915
Authors: C I Nagel; F J Backes; E M Hade; D E Cohn; E L Eisenhauer; D M O'Malley; J M Fowler; L J Copeland; R Salani Journal: Gynecol Oncol Date: 2011-11-04 Impact factor: 5.482
Authors: Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Juliette O A M van Baal; Cornelis J F van Noorden; Rienk Nieuwland; Koen K Van de Vijver; Auguste Sturk; Willemien J van Driel; Gemma G Kenter; Christianne A R Lok Journal: J Histochem Cytochem Date: 2017-11-22 Impact factor: 2.479
Authors: Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala Journal: Gynecol Oncol Date: 2015-06-17 Impact factor: 5.482
Authors: Marianne J Rutten; Katja N Gaarenstroom; Toon Van Gorp; Hannah S van Meurs; Henriette Jg Arts; Patrick M Bossuyt; Henk G Ter Brugge; Ralph Hm Hermans; Brent C Opmeer; Johanna Ma Pijnenborg; Henk Wr Schreuder; Eltjo Mj Schutter; Anje M Spijkerboer; Celesta Wm Wensveen; Petra Zusterzeel; Ben Willem J Mol; Gemma G Kenter; Marrije R Buist Journal: BMC Cancer Date: 2012-01-20 Impact factor: 4.430
Authors: R van de Laar; J IntHout; T Van Gorp; S Verdonschot; A M van Altena; C G Gerestein; L F A G Massuger; P L M Zusterzeel; R F P M Kruitwagen Journal: Br J Cancer Date: 2013-11-19 Impact factor: 7.640
Authors: Andrea E Wahner Hendrickson; Kieran M Hawthorne; Ellen L Goode; Kimberly R Kalli; Krista M Goergen; Jamie N Bakkum-Gamez; William A Cliby; Gary L Keeney; Daniel W Visscher; Yaman Tarabishy; Ann L Oberg; Lynn C Hartmann; Matthew J Maurer Journal: Gynecol Oncol Date: 2015-01-22 Impact factor: 5.482